BeyondSpring, Inc. (BYSI)
| Market Cap | 675.54M |
| Revenue (ttm) | 856,000 |
| Net Income (ttm) | -68.43M |
| Shares Out | 39.01M |
| EPS (ttm) | -1.92 |
| PE Ratio | n/a |
| Forward PE | 10.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 319,663 |
| Open | 16.75 |
| Previous Close | 16.75 |
| Day's Range | 16.04 - 16.87 |
| 52-Week Range | 8.90 - 33.00 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 65.60 (+305.2%) |
| Est. Earnings Date | Nov 17, 2021 |
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for BeyondSpring stock is "Strong Buy." The 12-month stock price forecast is 65.60, which is an increase of 305.19% from the latest price.
News
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in...
—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S.
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NC...
NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeuti...
Why Are BeyondSpring's Shares Plunging Today?
BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3 Phase 3 trial of plinabulin. The trial evaluated plinabulin combined with docetaxel vs.
Here's why BeyondSpring shares are up more than 25% on Monday
Shares of BeyondSpring Inc (NASDAQ: BYSI) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung canc...
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination...
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeut...
BeyondSpring Presents New Plinabulin Data At ESMO Congress
BeyondSpring Pharmaceuticals (NASDAQ: BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 2021 Co...
BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prev...
Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. Plinabulin in co...
BeyondSpring: Q2 Earnings Insights
BeyondSpring(NASDAQ:BYSI) stock fell by 4.13% on Monday after the company reported their Q2 earnings results on Friday, September 10, 2021 at 07:00 AM. Here's what investors need to know about the annou...
BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue Estimates
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
- Management to host a call today at 8:00 am ET - Management to host a call today at 8:00 am ET
Baird Initiates BeyondSpring With Outperform On Plinabulin Potential
BeyondSpring Inc's (NASDAQ:BYSI) lead candidate plinabulin is likely to receive approval around the Nov. 30 PDUFA date for chemotherapy-induced neutropenia (CIN), according to Baird. The BeyondSpring An...
BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at th...
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today annou...
BeyondSpring to Participate in the Upcoming September Conferences
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announ...
BYSI Stock: Why Did BeyondSpring Gain 15% on Tuesday?
Today, some very positive news surrounding BeyondSpring's lead drug candidate has sent shares of BYSI stock soaring. The post BYSI Stock: Why Did BeyondSpring Gain 15% on Tuesday?
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel C...
NEW YORK, Aug. 31, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announ...
Why BeyondSpring Stock Is Soaring This Week
A lucrative partnership deal with a pharmaceutical giant in China bodes well for BeyondSpring's potential new blockbuster cancer drug.
BeyondSpring Inks Plinabulin Agreement In Greater China
BeyondSpring Inc (NASDAQ: BYSI) and Jiangsu Hengrui Pharmaceuticals Co Ltd have entered into an exclusive commercialization and co-development agreement for plinabulin in Greater China. In combination w...
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals ...
NEW YORK and SHANGHAI, China, Aug. 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therap...
This Biotech Stock Just Skyrocketed by 170%. Is It a Buy?
Don't be too quick to pull the trigger.
Why BeyondSpring's Stock Is Soaring Higher
BeyondSpring Inc (NASDAQ: BYSI) shares are trading higher by 22.5% at $26.59 Friday afternoon on continued strength after the company earlier in the week announced results from its DUBLIN-3 trial of pli...
Why BeyondSpring Stock Skyrocketed Today
The biotech's experimental cancer therapy could be a game-changer.
These 2 Soaring Biotech Stocks Are Making the Nasdaq Stronger
The Nasdaq Composite is holding up better than its fellow market benchmarks.
BYSI Stock: The Huge Cancer News Sending BeyondSpring Skyrocketing Today
Shares of BYSI stock are soaring on Wednesday after pharmaceutical firm BeyondSpring released positive data regarding its lung cancer drug. The post BYSI Stock: The Huge Cancer News Sending BeyondSpring...
Why BeyondSpring's Stock Is Rallying Today
BeyondSpring Inc. (NASDAQ: BYSI) shares are trading higher after the company announced results from its DUBLIN-3 trial of plinabulin in combination with docetaxel for non-small cell lung cancer, which s...
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination w...
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, announced to...